Skip to main content
Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.4830
-0.0143 (-2.88%)
At close: Apr 25, 2025, 4:00 PM
0.4900
+0.0070 (1.45%)
Pre-market: Apr 28, 2025, 6:19 AM EDT

Calidi Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
--0.050.45-
Revenue Growth (YoY)
---89.98%--
Cost of Revenue
--0.010.09-
Gross Profit
--0.030.36-
Selling, General & Admin
12.915.9815.96.163.59
Research & Development
8.8813.017.263.83.18
Operating Expenses
21.7828.9923.169.966.77
Operating Income
-21.78-28.99-23.13-9.61-6.77
Interest Expense
-0.93-1.07-0.16-0.61-0.16
Other Non Operating Income (Expenses)
0.511.33-2.130.24-1.05
EBT Excluding Unusual Items
-22.2-28.73-25.42-9.98-7.99
Other Unusual Items
--0.47--0.060.06
Pretax Income
-22.2-29.2-25.42-10.92-7.93
Income Tax Expense
0.010.020.010.010
Earnings From Continuing Operations
-22.21-29.22-25.43-10.93-7.94
Minority Interest in Earnings
0.07----
Net Income
-22.14-29.22-25.43-10.93-7.94
Preferred Dividends & Other Adjustments
1.67----
Net Income to Common
-23.81-29.22-25.43-10.93-7.94
Shares Outstanding (Basic)
82122
Shares Outstanding (Diluted)
82122
Shares Change (YoY)
374.79%98.24%-56.93%15.26%-
EPS (Basic)
-2.97-17.33-29.90-5.54-4.63
EPS (Diluted)
-2.97-17.33-29.90-5.54-4.63
Free Cash Flow
-19.71-27.57-13.64-7.98-5.18
Free Cash Flow Per Share
-2.46-16.35-16.04-4.04-3.02
Gross Margin
--68.89%79.06%-
Operating Margin
---51395.56%-2139.42%-
Profit Margin
---56504.44%-2434.97%-
Free Cash Flow Margin
---30315.56%-1777.28%-
EBITDA
-21.37-28.6-22.87-9.45-6.67
D&A For EBITDA
0.40.390.260.160.11
EBIT
-21.78-28.99-23.13-9.61-6.77
Revenue as Reported
--0.05--
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q